Orion Animal Health receives FDA approval for Bonqat® (pregabalin oral solution)
20 Noviembre 2023 - 7:00AM
Orion Animal Health receives FDA approval for Bonqat® (pregabalin
oral solution)
ORION CORPORATION PRESS RELEASE 20 NOVEMBER 2023 at 15.00
EET
Orion Animal Health receives FDA approval for Bonqat®
(pregabalin oral solution)
Orion Corporation today announced that the U.S. Food and
Drug Administration (FDA) has granted approval of Bonqat®
(pregabalin oral solution) for alleviation of
acute anxiety and fear associated with transportation and
veterinary visits in cats.
Pregabalin is a new active substance for veterinary use and it
acts in the central nervous system by reducing the release of
various neurotransmitters (glutamate and monoaminergic
neurotransmitters), resulting in an anxiolytic effect.
Orion’s long-standing strategic partner, Zoetis, has the
exclusive right to market and sell Bonqat in the United States.
Bonqat is anticipated to be available in the U.S. by mid-2024.
About OrionOrion is a globally operating
Finnish pharmaceutical company – a builder of well-being. We
develop, manufacture and market human and veterinary
pharmaceuticals and active pharmaceutical ingredients. Orion has an
extensive portfolio of proprietary and generic medicines and
self-care products. The core therapy areas of our pharmaceutical
R&D are oncology and pain. Proprietary products developed by
Orion are used to treat cancer, neurological diseases and
respiratory diseases, among others. Orion's net sales in 2022
amounted to EUR 1,341 million and the company had about 3,500
employees at the end of the year. Orion's A and B shares are listed
on Nasdaq Helsinki.
About ZoetisAs the world’s leading animal
health company, Zoetis is driven by a singular purpose: to nurture
our world and humankind by advancing care for animals. After
innovating ways to predict, prevent, detect, and treat animal
illness for more than 70 years, Zoetis continues to stand by those
raising and caring for animals worldwide – from veterinarians and
pet owners to livestock farmers and ranchers. The company’s leading
portfolio and pipeline of medicines, vaccines, diagnostics and
technologies make a difference in over 100 countries. A Fortune 500
company, Zoetis generated revenue of $8.1 billion in 2022 with
approximately 13,800 employees. For more information, visit
www.zoetis.com.
Contact
person:Tuukka Hirvonen, Investor RelationsOrion
Corporationtel. +358 10 426 2721e-mail:
tuukka.hirvonen@orion.fi
Publisher:Orion
CorporationCommunicationsOrionintie 1A, FI-02200 Espoo,
Finlandwww.orion.fi
Orion (BIT:1ORNBV)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Orion (BIT:1ORNBV)
Gráfica de Acción Histórica
De May 2023 a May 2024